DONATE

IMMONC at the SIOP Asia 2023 Congress

The Immune Oncology Research Institute was an Organizer of SIOP Asia 2023 Congress, that took place in Yerevan, Armenia, May 18-21. Our team members not only participated as speakers during the congress but also actively contributed to the Organizing and Scientific Committees.

Gevorg Tamamyan, our CEO, served as the Chairman of the Organizing Committee and utilized the platform to present IMMONC and POEM Group. Ruzanna Papyan, a Clinical Researcher, held the position of Co-chair of the Scientific Committee and delivered a speech on the comparison of MTX-based and Carboplatin-based protocols in the management of osteosarcoma, specifically dedicated to the celebration of POEM's 10th anniversary.

Samvel Bardakhchyan, our Scientific Director, presented a comprehensive overview of the treatment of pediatric CNS tumors in Armenia over the past 26 years. Karen Bedirian, our Project Director, focused on the topic of special study populations.

Astghik Voskanyan, another Clinical Researcher from our team, showcased the BPDCN international registry, where she serves as the Principal Investigator. Our fellow Julia Hoveyan introduced the International Registry of Rare Embryonal Tumors of CNS, for which she also acts as a Principal Investigator. Shushan Hovsepyan, another fellow, presented her research abstract on vincristine-induced peripheral neuropathy in children with cancer.

In addition to this, one of the Meet the Professor Sessions featured Justin Stebbing, a board member of IMMONC, who also had a speech about "Thinking out of the box: learning from the COVID-19 pandemic", and shared his insights about giving an effective presentation: using powerpoint and structuring a scientific talk.

Overall, this congress served as an excellent opportunity for IMMONC to forge new international connections and pursue further growth in the field.


About IMMONC

Immune Oncology Research Institute (IMMONC) is dedicated to advancing research aimed at preventing, treating, and ultimately curing cancer while making these innovations accessible to those who need them. If you're interested in joining our team, please feel free to contact us at [email protected] or at +374-41 310-048.